PDRN, a natural bioactive compound, blunts inflammation and positively reprograms healing genes in an "in vitro" model of oral mucositis.
Anti-Inflammatory Agents
/ pharmacology
Cells, Cultured
Cytokines
/ genetics
Epidermal Growth Factor
/ metabolism
Epithelial Cells
/ drug effects
Fibroblasts
/ drug effects
Gingiva
/ drug effects
Humans
Inflammation Mediators
/ metabolism
Mouth Mucosa
/ drug effects
Polydeoxyribonucleotides
/ pharmacology
Stomatitis
/ drug therapy
Vascular Endothelial Growth Factor A
/ metabolism
Wnt Signaling Pathway
Wound Healing
/ drug effects
A(2A) receptor
Inflammation
Oral mucositis
Polydeoxyribonucleotide
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
27
01
2021
revised:
23
02
2021
accepted:
21
03
2021
entrez:
27
7
2021
pubmed:
28
7
2021
medline:
4
8
2021
Statut:
ppublish
Résumé
Oral mucositis is a side effect hard to treat following high dose chemotherapy or radiotherapy. Adenosine A
Identifiants
pubmed: 34311536
pii: S0753-3322(21)00323-1
doi: 10.1016/j.biopha.2021.111538
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Inflammation Mediators
0
Polydeoxyribonucleotides
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Epidermal Growth Factor
62229-50-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111538Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.